Assenagon Asset Management S.A. Has $48,000 Holdings in Neuronetics, Inc. $STIM

Assenagon Asset Management S.A. cut its holdings in Neuronetics, Inc. (NASDAQ:STIM) by 85.9% during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 13,761 shares of the company’s stock after selling 83,895 shares during the quarter. Assenagon Asset Management S.A.’s holdings in Neuronetics were worth $48,000 at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of the business. Larson Financial Group LLC acquired a new stake in Neuronetics in the first quarter valued at about $25,000. KPP Advisory Services LLC acquired a new stake in shares of Neuronetics during the first quarter valued at about $37,000. FORA Capital LLC acquired a new stake in shares of Neuronetics during the first quarter valued at about $42,000. National Bank of Canada FI boosted its stake in shares of Neuronetics by 19,491.5% during the first quarter. National Bank of Canada FI now owns 11,559 shares of the company’s stock valued at $42,000 after purchasing an additional 11,500 shares in the last quarter. Finally, Fermata Advisors LLC acquired a new stake in shares of Neuronetics during the second quarter valued at about $52,000. 53.59% of the stock is owned by institutional investors and hedge funds.

Neuronetics Price Performance

Shares of STIM opened at $2.71 on Monday. Neuronetics, Inc. has a 1 year low of $0.52 and a 1 year high of $5.92. The company has a debt-to-equity ratio of 1.76, a current ratio of 2.02 and a quick ratio of 1.84. The company has a market capitalization of $179.19 million, a price-to-earnings ratio of -2.40 and a beta of 1.28. The business has a 50-day moving average of $3.58 and a 200-day moving average of $3.82.

Neuronetics (NASDAQ:STIM) last issued its quarterly earnings data on Tuesday, August 5th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.07). Neuronetics had a negative return on equity of 156.36% and a negative net margin of 43.47%.The company had revenue of $38.11 million for the quarter, compared to the consensus estimate of $36.80 million. Neuronetics has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. As a group, equities research analysts anticipate that Neuronetics, Inc. will post -1.13 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Separately, Canaccord Genuity Group cut their price target on Neuronetics from $8.00 to $7.00 and set a “buy” rating on the stock in a research note on Wednesday, August 6th. One analyst has rated the stock with a Buy rating, According to data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $7.00.

About Neuronetics

Neuronetics, Inc, a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder.